Google
Trusted Resources: News & Events
Latest announcements and gatherings
Virtual Reality Helps Reduce Pain Among Patients With Sickle Cell Disease
Immersive virtual reality appeared effective as a complementary therapy to manage vasoocclusive pain among patients with sickle cell disease.
“In addition to standard therapies, virtual reality may help reduce the pain experience with sickle cell disease vasoocclusive pain episodes,” Anne Marsh, MD, director of the Pediatric Sickle Cell Clinic and associate hematologist/oncologist at UCSF Benioff Children’s Hospital Oakland, and colleagues wrote. “Further study is required to determine the impact of virtual reality therapy on opioid usage and length of stay in hospital.”
Marsh and colleagues sought to determine whether immersive virtual reality could be a feasible treatment approach for a cohort of 30 patients (median age, 16 years; 21 female) with sickle cell disease hospitalized for vasoocclusive pain episodes.
Results showed pain intensity dropped significantly after a single virtual reality session. Investigators observed improvement in sensory, affective, evaluative and temporal pain domains (P .01 for all).
+myBinderRelated Content
-
Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with...While acute episodic pain is the hallmar...
-
Vaso-Occlusive Crises and Costs of Sickle Cell Disease in Patients With Commercial, Medicaid and Medicare Insurance ...Aim: To characterize vaso-occlusive cri...
-
New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Cr...SANGUINATE™, the only investigational ...
-
Gut Microbiome Translates Stress Into Sickle Cell CrisesA new study shows how chronic psychologi...
-
SCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
-
Sickle Cell Disease: Why Is It Hard to Talk About Our Pain?https://www.youtube.com/watch?v=63pgiclv...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.